Tangent Medical Technologies has landed millions of dollars more in seed capital thanks to a $8.6 million Series B round. The seed-capital round was also lead by Ann Arbor Arboretum Ventures.
"We're getting ready to commercialize the product," says Jeff Williams, CEO of
Tangent Medical Technologies.
The Series B round of venture capital comes on the heels of Tangent Medical Technologies receiving FDA 510(k) clearance for the NovaCath Secure IV Catheter System. Tangent Medical Technologies' product integrates a series of next-generation technologies designed to address IV therapy challenges including catheter stabilization, healthcare worker safety, tubing management and patient comfort. NovaCath's passive needle shielding technology and closed system design is meant to minimize risk of needlestick injuries and occupational exposure to blood to the lowest feasible extent.
Williams declined to comment on how many people work at Tangent Medical Technologies but did say the company "has hired a few people" over the last year.
Source: Jeff Williams, CEO of Tangent Medical Technologies
Writer: Jon Zemke
Read more about Metro Detroit's growing entrepreneurial ecosystem at SEMichiganStartup.com.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.